Mariana P. Socal

Nov 15, 2024 | jamanetwork.com | Joseph Levy |Mariana P. Socal

Introduction State Medicaid receives pharmaceutical base and inflation rebates (eMethods in Supplement 1).1,2 Until recently, rebates were capped at the mean price manufacturers sell to wholesalers (average manufacturer price [AMP]).

Sep 26, 2024 | jamanetwork.com | Elizabeth Plummer |Fort Worth |Mariana P. Socal |Ge Bai

Key PointsQuestion  What is the total tax benefit received by US nonprofit hospitals? Findings  Analyzing data from Medicare Cost Reports, a total of 2927 US nonprofit hospitals received a $37.4 billion total tax benefit in 2021. Tax benefit varies widely across states and is highly concentrated among a small number of hospitals. More than half of the total tax benefit was received at the state and local levels.

Apr 29, 2024 | jamanetwork.com | Mariana P. Socal |Matthew A. Crane |Gerard F. Anderson

Active pharmaceutical ingredients (APIs) are a main component and a key determinant of the quality of prescription drugs.1 In 2014, 9% of drug shortages were attributed to the unavailability of APIs.2 In addition, APIs could potentially be linked to the 40% of shortages attributed to quality problems and the 30% caused by manufacturing delays and capacity issues.1,2 Few recent studies have examined the prevalence or characteristics of shortages due to APIs. As generic drugs constituted about...

Dec 14, 2023 | jamanetwork.com | Mariana P. Socal |Elizabeth Plummer |Fort Worth |Gerard F. Anderson

Spending on Dual Over-the-Counter and Prescription Drugs in the Medicare Part D Program Formulary Placement of Branded Drugs in Medicare Prescription Drug Plans When Generics Are Available Mariana P. Socal, MD, MS, MPP, PhD; Ge Bai, PhD, CPA; Gerard F. Anderson, PhD Estimating Savings Opportunities From Therapeutic Substitutions for High-Cost Generic Medications Mariana P.

Sep 27, 2023 | jamanetwork.com | Mariana P. Socal |Gerard F. Anderson |Emily Harris |Ilina C. Odouard

An amyloid-directed monoclonal antibody, lecanemab-irmb (Leqembi), was approved by the US Food and Drug Administration (FDA) on July 6, 2023, to treat Alzheimer disease with mild cognitive impairment or mild dementia.